Resistance mutation in HIV entry inhibitors

AIDS

Volumn 16, Issue 12, 2002, Pages 1603-1608

  Hanna, Sheri L ^a   Yang, Chunfu ^a   Owen, Sherry M ^a   Lal, Renu B ^a,b  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b Immunopathogenesis Laboratory   (United States)

Author keywords

Entry inhibitors; HIV 1; Resistant mutations

Indexed keywords

ANTIRETROVIRUS AGENT; ENFUVIRTIDE; GLYCOPROTEIN GP 41; MEMBRANE PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; VIRUS MUTATION;

AMINO ACID SEQUENCE; DRUG RESISTANCE, MICROBIAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MEMBRANE FUSION; MOLECULAR SEQUENCE DATA;

EID: 0037119035     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200208160-00005     Document Type: Article

References (22)

1. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects
2. Transmission of antiretroviral-drug-resistant HIV-1 variants
3. HIV entry and its inhibition
4. Chemokine receptors as HIV-1 coreceptors: Role in viral entry, tropism and disease
5. Co-receptors for HIV-1 entry
6. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication
7. Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type-1?
8. Peptide corresponding to a predictive alpha-helical domain of HIV-1 gp41 are potent inhibitors of virus infection
9. Protein design of an HIV-1 entry inhibitor
10. Peptides corresponding to the heptad repeat motifs in the transmembrane (gp41) of human immunodeficiency/virus type 1 elicit antibodies to receptor-activated conformations of the envelope
11. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
12. Core structure of gp41 from the HIV envelope glycoprotein
13. Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation
14. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding
15. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides
16. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120
17. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor
18. Analysis of genetic variability within the immunodominant epitopes of envelope gp41 from human immunodeficiency virus type 1 (HIV-1) group M and its impact on HIV-1 antibody detection
19. Detection of diverse variants of HIV-1 groups M, N, and O and simian immunodeficiency viruses from chimpanzees using generic pol and env primer pairs
20. Prolonged therapy with the fusion inhibitor T-20 in conjunction with oral antiretroviral agents in an HIV-infected individual
21. Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patient
22. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion